Highly diluted medication reduces parasitemia and improves experimental infection evolution by  by unknown
Highly diluted medication reduces parasitemia
and improves experimental infection evolution by
Trypanosoma cruzi
Aleixo et al.
Aleixo et al. BMC Research Notes 2012, 5:352
http://www.biomedcentral.com/1756-0500/5/352 (11 July 2012)
Aleixo et al. BMC Research Notes 2012, 5:352
http://www.biomedcentral.com/1756-0500/5/352RESEARCH ARTICLE Open AccessHighly diluted medication reduces parasitemia
and improves experimental infection evolution by
Trypanosoma cruzi
Denise Lessa Aleixo1*, Fabiana Nabarro Ferraz1, Érika Cristina Ferreira1, Marta de Lana2, Mônica Lúcia Gomes1,
Benício Alves de Abreu Filho3 and Silvana Marques de Araújo1Abstract
Background: There is no published information about the use of different protocols to administer a highly
diluted medication.
Evaluate the effect of different protocols for treatment with biotherapic T. cruzi 17 dH (BIOTTc17dH) on
clinical/parasitological evolution of mice infected with T. cruzi-Y strain.
Methods: A blind, randomized controlled trial was performed twice, using 60 28-day-old male Swiss mice infected
with T. cruzi-Y strain, in five treatment groups: CI - treated with a 7% ethanol-water solution, diluted in water
(10 μL/mL) ad libitum; BIOTPI - treated with BIOTTc17dH in water (10 μL/mL) ad libitum during a period that started
on the day of infection; BIOT4DI - treated with BIOTTc17dH in water (10 μL/mL) ad libitum beginning on the 4th day of
infection; BIOT4-5–6 - treated with BIOTTc17dH by gavage (0.2 mL/ animal/day) on the 4
th, 5th and 6th days after
infection; BIOT7-8–9 - treated with BIOTTc17dH by gavage (0.2 mL/ animal/day) on the 7
th, 8th and 9th days after
infection. We evaluated: parasitemia; total parasitemia (Ptotal); maximum peak of parasites; prepatent period
(PPP) - time from infection to detection of the parasite in blood; patent period (PP) - period when the parasitemia
can be detected in blood; clinical aspects; and mortality.
Results: Parasitological parameters in the BIOTPI and mainly in the BIOT4PI group showed better evolution of the
infection compared to the control group (CI), with lower Ptotal, lower maximum peak of parasites, higher PPP, lower
PP and longer survival times. These animals showed stable body temperature and higher weight gain and water
consumption, with more animals having normal-appearing fur for longer periods. In contrast, groups BIOT4-5–6 and
BIOT7-8–9 showed worse evolution of the infection compared to the control group, considering both parasitological
and clinical parameters. The correlation analysis combined with the other data from this study indicated that the
prepatent period is the best parameter to evaluate the effect of a medication in this model.
Conclusions: The BIOT4DI group showed the best clinical and parasitological evolution, with lower parasitemia and
a trend toward lower mortality and a longer survival period. The prepatent period was the best parameter to
evaluate the effect of a medication in this model.
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The use of highly diluted medications in the treatment
of parasitic diseases has been investigated, but the avail-
able information does not allow us to demonstrate
details of their effects. One of the hypotheses regarding
the therapeutic effect of these drugs is that they modu-
late the immune system, and understanding the dynam-
ics of this effect depends on the recognition of the
information systems involved [1,2]. Bellavite et al. (2007)
[3] suggested that homeopathic medicine can regulate
inflammatory and immunopathological processes as well
as the neuroendocrine network and peripheral receptors.
Specifically in mice infected with T. cruzi, one study
reported an increase in the apoptosis rate and a decrease
in the secretion of TGF-β measured in serum collected
from the group treated with biotherapic medication,
compared with the control group [4].
Although several studies have attempted to explain the
clinical results of highly diluted medications, few trials
have evaluated the effect of different treatment schemes
with these drugs on living organisms [5-7].
Biotherapics are highly diluted medications prepared
according to homeopathic techniques [8] from biological
products, including the etiological agent itself [9]. Al-
though experience in clinical practice using biotherapics
cannot be ignored, academic research on biotherapics
has been questioned [10].
Chagas disease, caused by the protozoan Trypanosoma
cruzi, has been studied for more than a century. How-
ever, no effective drug for etiological treatment has been
discovered so far [11].
T. cruzi-Y is considered a reference strain [12]. Exten-
sively studied in experimental murine models, it shows
well-defined characteristics such as high parasitemia, peak
of parasites by the 12th day of infection, death of all un-
treated infected animals, and partial resistance to drugs
classically used in the treatment of human Chagas disease.
Therefore, the murine model is an excellent experimental
model for the evaluation of drug interventions [13].
According to the literature, morbidity is related to the
presence of the parasite [14,15], and pathogenesis increase
is the result of a disruption of the host-parasite relationship
[16]. Therefore, using biotherapics as an intervention in
murine infection with T. cruzi is a possible means to
understand the effect of these highly diluted medications
and to find new candidates to treat Chagas disease.
The present study evaluated in vivo the effect of differ-
ent treatment schemes using the biotherapic Trypanosoma
cruzi 17dH (BIOTTc17dH) in an experimental infection by
this protozoan.
Results and discussion
As far as we are aware, this is the first study to compare
different treatment schemes using a biotherapic T. cruziin murine infection by the protozoan. Evaluation of
parasitological and clinical parameters showed that the
different treatment schemes using this medicine produced
different profiles in the evolution of the infection of the Y
strain of T. cruzi in Swiss mice.Parasitological parameters
The mean and standard deviation of the parasitological
parameters for each group are shown in Tables 1 and 2.
The evolution of parasitemia in groups of animals trea-
ted with biotherapics diluted in water ad libitum for a
long period (BIOTPI and BIOT4PI) showed better evolu-
tion of the infection compared to the control group (CI).
Compared to the control group, animals treated with
BIOTPI and mainly BIOT4PI showed lower values of area
under the curve of daily parasitemia (BIOTPI p < 0.01
and BIOT4PI p < 0.01), lower total parasitemia (BIOTPI
p < 0.01 and BIOT4PI p < 0.01), and lower maximum
peaks of parasites (BIOTPI p < 0.01 and BIOT4PI p < 0.01)
(Table 1). There was no statistical difference in parasit-
emia on the 8th day of infection and in the 2nd peak of
parasites for the BIOTPI and BIOT4PI groups compared
to the control, as well as in the percentage of animals
that showed the 2nd maximum peak of parasites. These
are characteristics typical of infection by the T. cruzi-Y
strain: a peak of parasites on the 8th day of infection and
a second, lower peak of parasites, later. This second peak
occurred earlier in BIOTPI and BIOT4PI than in the con-
trol group. Considering the parameters shown in Table 2,
compared to the control group, the BIOTPI and mainly
BIOT4PI groups showed longer prepatent periods
(BIOT4PI p < 0.01 and BIOTPI p = 0.13) and shorter patent
periods (BIOTPI p < 0.01 and BIOT4PI p < 0.01), longer
survival times, significant for the BIOT4PI group (p < 0.01)
and a lower (although not significantly lower) mortality.
Together, these results show a better outcome of the in-
fection, since the parasitemia in infection by T. cruzi is
directly proportional to morbidity [17].
In contrast, the BIOT4-5–6 and BIOT7-8–9 groups
showed a worse evolution of the infection compared to
the control group. The area under the curve of daily
parasitemia in these groups did not differ from the value
observed for the control group (p = 0.99), and similarly
for total parasitemia (p = 0.99). The BIOT4-5–6 and
BIOT7-8–9 groups showed a higher maximum peak of
parasites, significantly higher in the BIOT4-5–6 group, as
well as a significant advancement of this maximum peak
(p < 0.01). There was no significant difference in the
parasitemia peak on the 8th day of infection, the parasit-
emia of the 2nd peak of parasites, nor in the percentage
of animals that showed the 2nd peak for the BIOT4-5–6
and BIOT7-8–9 groups compared to the control group.
The prepatent period and survival was lower for these
Table 1 Parasitological parameters of animals subjected to different treatment schemes using biotherapic (BIOTTc17dH)
GROUP AUC (x105) Ptotal (x10
6) Pmax (x10
6) DAY OF Pmax P8thDI (x10
6) 2nd Pmax (x10
4) DAY OF 2nd PEAK 2nd PEAK n/N (%)
CI 10.9±8.20 12.5±8.98 5.02±7.07 10.76±3.15 2.82±3.12 11.0±10.2 14.03±2.63 8/12 (66%)
BIOT4-5-6 9.23±3.26 9.33±3.25 5.82±2.14** 8.25±0.67** 5.11±2.62 2.10±17.4 12.0±2.0* 4/12 (33%)
BIOT7-8-9 8.78±2.34 9.32±2.48 4.05±2.42 8.64±0.71** 3.96±2.51 17.4±0 14.25±1.02 8/12 (66%)
BIOTPI 5.95±4.55** 6.63±5.02** 2.25±1.65** 15.46±23.06 1.62±1.69 11.1±13.6 13.67±0.63* 6/12 (50%)
BIOT4PI 4.28±2.89** 4.63±3.19** 1.45±1.00** 10.27±2.03 1.01±0.96 7.09±10.2 12.8±0.68* 6/12 (50%)
Statistical significance (p < 0.05* and p< 0.01**) compared to control group: CI: control group – infected animals treated with 7% ethanol-water solution diluted in water (10μL/mL) offered ad libitum; BIOTPI: infected
animals treated with biotherapic BIOTTc17dH diluted in water (10μL/mL) offered ad libitum from the day of the infection until the death of the animals; BIOT4PI: infected animals treated with biotherapic BIOTTc 17dH
diluted in water (10μL/mL) offered ad libitum from the 4th day of the infection until the death of the animals; BIOT4-5–6: infected animals treated with biotherapic BIOTTC 17dH by gavage on the 4
th, 5th and 6th day of
the infection; BIOT7-8–9: infected animals treated with biotherapic BIOTTC 17dH by gavage on the 7
th, 8th and 9th day of the infection. AUC= area under the curve (parasites/ mL); Ptotal = total parasitemia (parasites/ mL);
Pmax =maximum peak of parasites (parasites/ mL); Day of Pmax =Day of maximum peak of parasites; P8thDI = number of tripomastigotes on 8
th day of infection (parasites/ mL); 2nd Pmax = number of tripomastigotes in
the 2nd peak of parasites (parasites/ mL); Day of 2nd Pmax =Day of 2




















Table 2 Prepatent period (PPP), patent period (PP),
survival and percent mortality of animals subjected to
different treatment schemes using biotherapic
(BIOTTc17dH)
GROUP PPP (days) PP (days) SURVIVAL (days) DEATH n/N (%)
CI 6.02±1.85 9.63±2.74 15.33±3.39 12/12 (100%)
BIOT4-5-6 3.86±1.36* 7.43±1.99* 12.14±1.25* 12/12 (100%)
BIOT7-8-9 4.38±1.32* 8.88±1.62 14±1.5 12/12 (100%)
BIOTPI 13.67±33.11 6.61±2.69** 29±42.79 10/12 (83%)
BIOT4PI 21.5±42.87** 5.78±1.03** 27.1±40.98** 11/12 (92%)
Statistical significance (p < 0.05* and p< 0.01**) compared to control group:
CI: control group – infected animals treated with 7% ethanol-water solution
diluted in water (10μL/mL) offered ad libitum; BIOTPI: infected animals treated
with biotherapic BIOTTc17dH diluted in water (10μL/mL) offered ad libitum from
the day of the infection until the death of the animals; BIOT4PI: infected
animals treated with biotherapic BIOTTc 17dH diluted in water (10μL/mL)
offered ad libitum from the 4th day of the infection until the death of the
animals; BIOT4-5–6: infected animals treated with biotherapic BIOTTC 17dH by
gavage on the 4th, 5th and 6th day of the infection; BIOT7-8–9: infected animals
treated with biotherapic BIOTTC 17dH by gavage on the 7
th, 8th and 9th day of
the infection.
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the animals, as also observed for the control (Table 2).
Considering the 12 parameters shown in Tables 1 and 2,
the BIOT4PI group showed the best overall performance.
In this study, the data obtained for the animals treated
with highly diluted medications in the more appropriate
treatment schemes (BIOTPI and BIOT4PI) showed better
results than those observed in the control group. Not-
ably, in the BIOTPI and BIOT4PI groups (which showed
better evolution of the infection) there was a significant
individual variation observed among the animals of
the same group, as shown by the standard deviations
(Tables 1 and 2). This individual variation was also
observed in the control group.
These data suggest that some animals naturally
evolve with lower parasitemia levels, while other ani-
mals evolve with higher parasitemia levels. The more-
appropriate treatment schemes using highly diluted
medications seemed to favor those animals with a
tendency to develop lower parasitemia levels. This
phenomenon may have led to the result in which the
treatment of the BIOT4PI or BIOTPI groups produced
a decrease in the parasitemia levels and a tendency to a
lower mortality level with a longer survival period. This
contrasts with the study by Sandri et al. (2010) [18], where
a different treatment scheme was used in the same experi-
mental conditions.
Clinical parameters
The groups of animals that were given the medication
(BIOTTc17dH) in water ad libitum for a long period
showed better clinical evolution, with a stable body
temperature (p < 0.05), higher weight gain (p < 0.01) and
higher water consumption (p < 0.05) compared to thecontrol group. The groups treated for a long period
(BIOTPI and BIOT4PI) contained more animals with
‘normal-looking’ fur for longer periods during the
study, and the BIOT4PI group showed the best results
of all. In the BIOT4-5–6 and BIOT7-8–9 groups, more
animals showed bristling hair, with a similar evolution
to the control group (CI).
In murine T. cruzi infection, the morbidity is linked to
parasitemia [17]. However, the host-parasite relationship
is essential for the manifestation of the disease, which
appears more lethal when the balance of this relation-
ship is jeopardized.
The functional recovery of complex biological sys-
tems occurs in an integrated manner (considering the
psycho-neuro-immuno-endocrine-metabolic axis), and
sometimes the imbalance of one part is necessary to
maintain the balance as a whole, with the appearance
of new signs and/or exacerbating old symptoms or man-
ifestations [19].
In this context, the host immune response causes
many symptoms of the infection [20,21], and may help
to explain the discrepancy between virulence and para-
site loads [22,23], suggesting new prospects for the ad-
vancement of these studies.Survival evaluation
Three animals survived in the groups that were given
the medication (BIOTTc17dH) in water ad libitum for a
long period. Of these three survivors, two were from the
BIOTPI group, and only one of them had patent parasit-
emia. The other had negative PCR (Polymerase Chain
Reaction) [24], understood as a protective action of the
drug, since the treatment began at the time of the infec-
tion. Considering that the T. cruzi-Y strain shows 100%
infectivity and mortality in Swiss mice [12,25-27] this re-
sult shows a patent benefit of the medication.
The surviving animal in the BIOT4PI group, although
it showed a positive PCR diagnosis, never showed patent
parasitemia. This result is consistent with low levels of
parasitemia and provides information about the benefit
of the treatment scheme used, since survival in the mur-
ine model is directly related to parasitemia levels [27].
The better evolution of the infection, considering both
parasitological and clinical parameters in BIOTPI and
mainly in BIOT4PI is expressed by the delayed onset of
mortality (16th and 13th day of infection, respectively) as
well as the lower mortality compared to the control
group. The survival of 3 animals for more than 360 days,
with a mean and standard deviation of 27.1 ± 40.98
(p < 0.01) and 29.0 ± 42.79 (p > 0.05) for the BIOT4PI and
BIOTPI groups (Table 2), respectively, suggests an
improved prognosis in a pathogenesis process that
shows an irreversible evolution [28].
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The correlation analysis indicates the relationship
between two variables within a group. The relation-
ships between each clinical or parasitological param-
eter (variable) and survival for the groups CI, BIOTPI
and BIOT4PI were evaluated separately. This relation
is expressed by a number called correlation coefficient
(‘r’), which can be significant or not. Their values
range from +1 to −1, and its size indicates the force
of correlation. Correlations up to 0.299 were consid-
ered weak, values from 0.300 – 0.499 were considered
intermediate, and strong from 0.500 – 0.999. The sig-
nal indicates the direction, if the correlation is posi-
tive (direct) or negative (inverse).
Considering that in this model, the evolution of the
disease is irreversible, culminating in the death of the
animals, an increase in the survival period is an indi-
cator of a good treatment scheme. Some clinical and / or
parasitological parameters may be more or less related
to this increase in survival. The correlation analysis may
indicate which are the more important parameters
that could be measured. Therefore, we evaluated the
correlations between the parasitological/clinical para-
meters and survival periods for the control group
(CI) and the groups treated with the biotherapic
(BIOTTc17dH) in the treatment schemes that improved
the clinical and parasitological evolution (BIOTPI and
BIOT4PI) (Table 3).Table 3 Values of correlation (‘r’) of parasitological and
clinical parameters with survival of animals subjected to
different treatment schemes using biotherapic
(BIOTTc17dH)
‘r’ FOR CORRELATION
PARAMETERS CI BIOTPI BIOT4PI
AUC (-)0.2250 (-)0.1980 (-)0.2349
Ptotal (-)0.3220 (-)0.4387 (-)0.5227
Pmax (-)0.2989 (-)0.3182 (-)0.5350
Day Pmax NS NS NS
PPP (+)0.4825 (+)0.6704 (+)0.9995
PP (+)0.7901 (-)0.7000 (-)0.8998
Ta NS NS NS
WEIGHT NS NS (+)0.4797
WATER NS NS NS
NS=no significant correlation. ‘r’ values are presented for significant
correlations (p < 0.05) between survival and the parameters: AUC = area under
the curve (parasites/mL); Ptotal – total parasitemia (parasites/ mL);
Pmax =maximum peak of parasites (parasites/ mL); Day of Pmax- Day of
maximum peak of parasites; PPP = Prepatent period; PP = patent period;
Ta = Temperature; Weight and Water. Groups: CI: control group – infected
animals treated with 7% ethanol-water solution diluted in water (10μL/mL)
offered ad libitum; BIOTPI: infected animals treated with biotherapic BIOTTc17dH
diluted in water (10μL/mL) offered ad libitum from the day of the infection
until the death of the animals; BIOT4PI: infected animals treated with
biotherapic BIOTTc17dH diluted in water (10μL/mL) offered ad libitum from the
4th day of the infection until the death of the animals.The prepatent period (PPP), patent period (PP) and
total parasitemia (Ptotal) showed moderate to strong cor-
relations with the survival period for all groups. For
shorter survival periods, the groups showed higher total
parasitemia (Ptotal). In groups treated for a long period,
the Ptotal was lower and showed increasing ‘r’ values
(BIOT4PI > BIOTPI >CI).
The prepatent period (PPP) was best correlated with
the survival period. The BIOT4PI group showed a strong
and positive correlation (r = 0.9995), indicating that the
survival was closely linked to an increase in the prepa-
tent period (PPP). In the different groups, this parameter
clearly reflected the differences in performance under
the different treatments, showing increasing 'r' values for
the BIOT4PI, BIOTPI and CI groups. This result, com-
bined with the set of data obtained in this study, indi-
cated that the PPP was the best parameter to evaluate an
intervention in this model.
This finding is important considering that in protocols
with highly diluted substances, researchers tend to
evaluate an excessive number of parameters in an at-
tempt to include the key change that shows a benefit,
since benefits may be perceived but cannot always be
measured. In the experimental protocol used in this
study, the risk of contamination and the workload
involved need to be optimized, and it is imperative to se-
lect parameters that show the best effects most clearly.
The other parameters evaluated showed weak correla-
tions with survival, although they also showed peculiar-
ities in the comparison among the experimental groups.
The maximum peak of parasites (Pmax) was inversely
correlated with the survival period; the relationship was
moderate for the CI and BIOTPI groups and strong for
the BIOT4PI group. These results concord with those for
the treatment schemes that began after the fourth day of
infection, and again indicate the importance of the treat-
ment scheme in determining the degree of morbidity
from the infection.
The correlation between the peak day and the survival
period had a particular result: the correlation was strong
and direct in the CI group, showing that the later the
peak of parasites, the longer is the survival time. In the
groups treated with the biotherapic, the correlation was
strong, but negative, with a higher ‘r’ value for the group
that performed best in this study (BIOT4PI > BIOTPI).
This fact is consistent with what we have observed in
previous studies: the biotherapic medications seem to
anticipate several important biological phenomena in the
course of experimental infection with T. cruzi [29]. The
high standard deviation observed for this parameter in
the BIOT4PI, BIOTPI and CI groups indicates the indi-
viduality of behavior for this parameter (Table 2). Sandri
et al. (2010) [18] has also observed this behavior indi-
viduality in both the treated and control group and
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infection had a higher sensitivity to the treatment. In the
case of Sandri et al. (2010) [18] the treatment scheme
was inadequate and resulted in increased parasitemia.
These results show that some parameters can work as
‘markers’ of the performance of an intervention in the
infection model used in this study, clearly reflecting the
evolution of infection and these parameters can be prior-
itized in the experimental design, minimizing the work
of researchers.
Although in this study in mice, the clinical parameters
of temperature, weight and water consumption, as mea-
sured, were not effective to clarify the best therapeutic
scheme using BIOTTc17dH, the researcher perceive the
difference among the groups. Find better methods to
evaluate these parameters is an important perspective.
Considering the groups of animals treated for long
periods, the BIOT4PI group presented a better perform-
ance with an intermediate correlation between weight
and survival. These data, besides reflecting more accur-
ately what was observed in the clinical evaluations, also
supports a good prognosis for animals treated with this
scheme.
Further discussions
The differences observed when comparing the evolution
of infection in the groups treated for a long period in
water (BIOTPI andBIOT4PI), and for a short period of
time by gavage (BIOT4-5–6 and BIOT7-8–9) show a better
balance for animals treated for longer periods in water.
The discussion of these results can also be based on the
fact that the medication administered in water for a long
period, besides enabling a higher number of stimuli, also
causes less stress to the animal compared to the treat-
ment by gavage, for a short period of time. Also in rela-
tion to medication administration, diluted in water, the
difference in the intake among the animals, although it
may be criticized, According to some authors, the con-
cept of medication dose as the amount of medication
that a patient must take to modify his state of illness is
not applicable to highly diluted medications, because
they do not act based on their mass, but rather by their
dynamic effect (qualitative), which continues for a
shorter or longer period according to the power of reac-
tion or sensitivity of the organism and the stage of the
disease [22,23].
Our data concord with the findings of other investiga-
tors that the use of highly diluted medications in the
acute phase of infection requires a higher frequency of
administered doses [23]. In a randomized controlled ex-
periment, the benefit of the treatment using highly
diluted medication continuously and for long periods
of time, without interruption of the stimulus, pro-
motes balance in acute infections [23].Considering that the stimulation provided by the highly
diluted medication is related to its ability to affect the psy-
cho-neuro-immune-endocrine-metabolic axis, stress may
also be a destabilizing factor that should be considered in
evaluating the results [15].
T. cruzi is an obligate intracellular parasite and its
interaction with the host cells is complex, and inflamma-
tion is a decisive component of the pathogenesis. In
developing resistance to T. cruzi, the immune system
can act through different routes that function more or
less effectively, depending on the conditions imposed by
the host-parasite relationship [17]. Sandri et al. (2011)
[30] demonstrated modulation of the inflammation
process in eight-week-old animals infected with T. cruzi
and treated with a biotherapic, with a higher rate of
apoptosis and reduced production of the cytokine trans-
forming growth factor beta (TGF-β).
In the present study, assuming that the highly diluted
medication BIOTTc17dH modulated the host immune sys-
tem, the finding that the best therapeutic result was
achieved with the medication administered beginning
after 4 days of infection and for long periods (BIOT4PI)
is consistent with the following hypothesis: In this
scheme, the host's immune system, already activated by
the parasite and affected by the highly diluted medica-
tion, leads the infection to evolve less aggressively, as
described by Sandri et al. (2011) [30].
Conclusion
The BIOT4DI group showed the best clinical and para-
sitological evolution, with lower parasitemia and a trend
toward lower mortality with longer periods of survival.
The PPP (prepatent period = time in days from the infec-
tion until the first parasite was detected in the blood)
proved to be the best parameter to evaluate the effect of
a medication in this model.
Methods
Animals and infection
The study involved 60, 28-day-old male Swiss mice from
the Central Animal Facility of the Universidade Estadual
de Maringá. The animals were infected intraperitoneally
with 1,400 blood trypomastigotes of T. cruzi-Y strain [12].
Groups according to treatment
The animals were divided equally into five groups accord-
ing to the treatment: CI - infected animals treated with 7%
ethanol-water solution diluted in water (10 μL/mL) offered
ad libitum in an amber bottle; BIOTPI -infected animals
treated with BIOTTc17dH diluted in water (10 μL/mL)
offered ad libitum in an amber bottle during a period that
started on the day of infection and finished when the ani-
mals died; BIOT4DI - infected animals treated with
BIOTTc17dH diluted in water (10 μL/mL) offered ad libitum
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death of the animals; BIOT4-5–6 - infected animals treated
with BIOTTc17dH administered by gavage (0.2 mL /
animal / day) on the 4th, 5th and 6th days after in-
fection; BIOT7-8–9 - infected animals treated with
BIOTTc17dH administered by gavage (0.2 mL / animal /
day) on the 7th, 8th and 9th days after infection.
The different treatment schemes were based on the ef-
fect of medication linked to the immunological effect
[3,18] and on the specific evolution of T. cruzi-Y strain
in Swiss mice [12,27]. Thus, BIOTPI and BIOT4PI simu-
lated a situation where the medication is offered
when the immunological system is not in contact with
the parasite, and a situation where the medication is
offered when the immunological system is already in
contact with the parasite, respectively. In BIOT4-5–6 and
BIOT7-8–9, the medication was offered to animals just
prior to the parasite peak and exactly coincident with
the parasite peak, respectively [12,27].
Experimental design
The experiment was performed twice as a blind rando-
mized controlled trial. The animals were divided into
separate cages so that the mean initial weights of mice
in each group were statistically equal. The animals were
kept in a climate-controlled vivarium, under controlled
temperature (22.7 ± 1.2 °C), light/dark cycles of 12 hours,
and water and food offered ad libitum.
Biotherapic T. cruzi 17 dH (BIOTTc17dH)
The highly diluted medication was produced from the
buffy coat of blood collected from the orbital plexus of
three mice, containing blood trypomastigotes on the 7th
day of infection with T. cruzi Y-strain. The BIOTTc17dH
was prepared by adding 0.9 mL of T. cruzi concentrate
(4.1 x 107 trypomastigotes /mL) in 9.1 mL of distilled
water in a 30-mL glass bottle. Subsequently, dilutions
were made in a 70% ethanol-water solution until the
16dH dynamization. The dynamization used, 17dH (cor-
responding to a dilution of 1:1017 of the initial suspen-
sion) was prepared with 7% ethanol-water solution. [8]
The microbiological test and the biological risk in vivo
were negative, according to the regulations of the Brazilian
Ministry of Health (RDC No. 67) [31], and the drug was
stored in amber glass for better conservation.
Parameters analyzed
Parasitological and clinical parameters were evaluated.
Parasitemia was evaluated by daily counts of blood try-
pomastigotes from the day of infection, using the tech-
nique of Brener (1962) [32]. For animals that showed
negative parasitemia, blood was collected for PCR diag-
nosis (Polymerase Chain Reaction) [24].Using the parasitemia curve, the following data were
obtained: prepatent period (PPP), which is the time from
infection to detection of the parasite in blood; patent
period (PP), the period when the parasitemia can be
detected; and total parasitemia (Ptotal), calculated as the
sum of the mean daily parasitemia levels for each mouse
in each group. The area under the curve (AUC), defined
as the number of parasites/ mL of blood observed at a
certain time of infection, was calculated using the soft-
ware Prism Graph 5. The peak of maximum parasitemia
(Pmax), considered the mean of the highest level of para-
sitemia observed in each animal throughout the ex-
periment, parasitemia on the 8th day of infection, the
2nd peak of parasites, and the percentage of occurrence
of this 2nd peak of parasites. The parasitemia was
expressed in parasites/ mL and the occurrence of this
2nd peak was expressed by the percentage of animals
that showed a peak (n) within a group (N). The day
on which these peaks occurred was also considered.
Mortality was computed during the course of the ex-
periment, resulting in the following parameters: days
of survival and percentage of mortality expressed by
the number of animals died (n) within a group (N).
The animals were clinically evaluated on alternate days
from the day of infection until the end of the treat-
ment for body temperature, water consumption, fur
appearance, and body weight [33].
Statistical analysis
The results were compared statistically using the program
Statistica 7.0, and the Kruskal-Wallis test (ANOVA fol-
lowed by multiple comparisons of mean ranks for all
groups) was used since the analyzed parameters did not
all show a normal distribution. The correlations were ana-
lyzed using the R.2.10 program. Correlations with ‘r’ value
up to 0.299 were considered weak, from 0.300 – 0.499 as
intermediate, and from 0.500 – 0.999 as strong. The ac-
ceptable level of significance was 5% for all analyses.
Ethics
The experiment was approved by the Ethics Committee
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